The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Olivier Bylicki
No relevant relationships to disclose
Celine Ferlay
No relevant relationships to disclose
Christos Chouaid
Honoraria - Amgen; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; Roche
Research Funding - Amgen; Lilly; Roche
Armelle Lavolle
No relevant relationships to disclose
Fabrice Barlesi
Consultant or Advisory Role - Roche
Honoraria - Lilly; Roche
Research Funding - Lilly
Radj Gervais
No relevant relationships to disclose
Virginie Westeel
Consultant or Advisory Role - Lilly; Roche
Honoraria - Boehringer Ingelheim; Lilly; Roche
Research Funding - Roche
Other Remuneration - AstraZeneca; Lilly; Roche
Jacky Crequit
No relevant relationships to disclose
Romain Corre
Honoraria - Lilly
Research Funding - Lilly
Alain Vergnenegre
Consultant or Advisory Role - Lilly; Roche
Gerard Zalcman
Consultant or Advisory Role - Lilly; Roche
Honoraria - Lilly; Roche
Isabelle Monnet
No relevant relationships to disclose
Herve Le Caer
Honoraria - Lilly; Roche
Pierre Fournel
Research Funding - Lilly
Pauline Linard
No relevant relationships to disclose
David Perol
Honoraria - Lilly; Roche
Maurice Perol
Consultant or Advisory Role - Lilly; Pfizer; Roche
Honoraria - Lilly; Roche
Research Funding - Lilly; Roche